Coadministrating luteolin minimizes the side effects of the aromatase inhibitor letrozole

Journal of Pharmacology and Experimental Therapeutics

Volumn 351, Issue 2, 2014, Pages 270-277

  Li, Fengjuan ^a,b   Wong, Tsz Yan ^c   Lin, Shu Mei ^d,f   Chow, Simon ^d   Cheung, Wing Hoi ^d   Chan, Franky L ^e   Chen, Shiuan ^g   Leung, Lai K ^c  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b Faculty of Science   (United States)

^c School of Biological Sciences   (China)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e Faculty of Pharmacy   (United States)

^f NATIONAL CHIAYI UNIVERSITY   (Taiwan)

^g CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; AROMATASE INHIBITOR; CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; ESTROGEN; HIGH DENSITY LIPOPROTEIN; LETROZOLE; LIPID; LUTEOLIN; PROTEIN BAX; PROTEIN BCL XL; APOPTOSIS REGULATORY PROTEIN; ESTRADIOL; NITRILE; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME KINETIC ASSAY; ESTROGEN BLOOD LEVEL; HUMAN; HUMAN CELL; LIPID BLOOD LEVEL; MOUSE; NONHUMAN; NUDE MOUSE; TUMOR XENOGRAFT; UNSPECIFIED SIDE EFFECT; ANIMAL; BLOOD; DRUG EFFECT; FEMALE; MCF 7 CELL LINE; METABOLISM; TUMOR CELL LINE;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; AROMATASE INHIBITORS; CELL CYCLE; CELL LINE, TUMOR; ESTRADIOL; FEMALE; LIPOPROTEINS, HDL; LUTEOLIN; MCF-7 CELLS; MICE; MICE, NUDE; NITRILES; TRIAZOLES;

EID: 84907186646     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.216754     Document Type: Article

References (38)

1. Azevedo MF, Camsari C, Sá CM, Lima CF, Fernandes-Ferreira M, and Pereira-Wilson C (2010) Ursolic acid and luteolin-7-glucoside improve lipid profiles and increase liver glycogen content through glycogen synthase kinase-3. Phytother Res 24 (Suppl 2):S220-S224.
2. Bell LN, Nguyen AT, Li L, Desta Z, Henry NL, Hayes DF, Wolff AC, Stearns V, Storniolo AM, and Flockhart DA; Consortium on Breast Cancer Pharmacogenomics (COBRA) (2012) Comparison of changes in the lipid profile of postmenopausal women with early stage breast cancer treated with exemestane or letrozole. J Clin Pharmacol 52:1852-1860.
3. Bonneterre J, Buzdar A, Nabholtz JMA, Robertson JFR, Thürlimann B, von Euler M, Sahmoud T,Webster A, and Steinberg M; Arimidex Writing Committee; Investigators Committee Members (2001) Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92:2247-2258.
4. Campos SM (2004) Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist 9:126-136.
5. Casagrande F and Darbon JM (2001) Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1. Biochem Pharmacol 61:1205-1215.
6. Choi EM (2007) Modulatory effects of luteolin on osteoblastic function and inflammatory mediators in osteoblastic MC3T3-E1 cells. Cell Biol Int 31:870-877.
7. Chow DH, Leung KS, Qin L, Leung AH, and Cheung WH (2011) Low-magnitude high-frequency vibration (LMHFV) enhances bone remodeling in osteoporotic rat femoral fracture healing. J Orthop Res 29:746-752.
8. Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, and Delmas PD (2007) Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 41:346-352.
9. Cuzick J (2003) Aromatase inhibitors in prevention-data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). Recent Results Cancer Res 163: 96-103.
10. Elisaf MS, Bairaktari ET, Nicolaides C, Kakaidi B, Tzallas CS, Katsaraki A, and Pavlidis NA (2001) Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 37:1510-1513.
11. Espeland MA, Marcovina SM, Miller V, Wood PD, Wasilauskas C, Sherwin R, Schrott H, and Bush TL (1998) Effect of postmenopausal hormone therapy on lipoprotein (a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Circulation 97:979-986.
12. Hernandez RK, Sørensen HT, Jacobsen J, Pedersen L, and Lash TL (2008) Tamoxifen treatment in Danish breast cancer patients and 5-year risk of arterial atherosclerotic events: a null association. Cancer Epidemiol Biomarkers Prev 17: 2509-2511.
13. Husdal A, Bukholm G, and Bukholm IRK (2006) The prognostic value and overexpression of cyclin A is correlated with gene amplification of both cyclin A and cyclin E in breast cancer patient. Cell Oncol 28:107-116.
14. Jeong HJ, Shin YG, Kim IH, and Pezzuto JM (1999) Inhibition of aromatase activity by flavonoids. Arch Pharm Res 22:309-312.
15. Ju YH, Doerge DR, Woodling KA, Hartman JA, Kwak J, and Helferich WG (2008) Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo. Carcinogenesis 29:2162-2168.
16. Keyomarsi K, OLeary N, Molnar G, Lees E, Fingert HJ, and Pardee AB (1994) Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 54:380-385.
17. Keyomarsi K and Pardee AB (1993) Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci USA 90:1112-1116.
18. Kim TH, Jung JW, Ha BG, Hong JM, Park EK, Kim HJ, and Kim SY (2011) The effects of luteolin on osteoclast differentiation, function in vitro and ovariectomyinduced bone loss. J Nutr Biochem 22:8-15.
19. Kobayashi T, Nakata T, and Kuzumaki T (2002) Effect of flavonoids on cell cycle progression in prostate cancer cells. Cancer Lett 176:17-23.
20. Leung LK and Wang TT (1999) Paradoxical regulation of Bcl-2 family proteins by 17beta-oestradiol in human breast cancer cells MCF-7. Br J Cancer 81:387-392.
21. Li F, Ye L, Lin SM, and Leung LK (2011) Dietary flavones and flavonones display differential effects on aromatase (CYP19) transcription in the breast cancer cells MCF-7. Mol Cell Endocrinol 344:51-58.
22. Lim Y, Jeong Y, Tyner AL, and Park JH (2007) Induction of cell cycle arrest and apoptosis in HT-29 human colon cancer cells by the dietary compound luteolin. Am J Physiol Gastrointest Liver Physiol 292:G66-G75.
23. Lindahl B, Andolf E, Ingvar C, Ranstam J, and Willén R (2008) Adjuvant tamoxifen in breast cancer patients affects the endometrium by time, an effect remaining years after end of treatment and results in an increased frequency of endometrial carcinoma. Anticancer Res 28 (2B):1259-1262.
24. Liu JF, Ma Y, Wang Y, Du ZY, Shen JK, and Peng HL (2011) Reduction of lipid accumulation in HepG2 cells by luteolin is associated with activation of AMPK and mitigation of oxidative stress. Phytother Res 25:588-596.
25. McCaig FM, Renshaw L, Williams L, Young O, Murray J, Macaskill EJ, McHugh M, Hannon R, and Dixon JM (2010) A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Res Treat 119:643-651.
26. Morgan DO (1995) Principles of CDK regulation. Nature 374:131-134.
27. Nasr A and Breckwoldt M (1998) Estrogen replacement therapy and cardiovascular protection: lipid mechanisms are the tip of an iceberg. Gynecol Endocrinol 12: 43-59.
28. Nicolaides C, Elisaf M, Bairaktari E, Kakaidi V, Katsaraki A, and Pavlidis N (2000) The effect of the aromatase inhibitor letrozole on lipid parameters in postmenopausal women with metastatic breast cancer. A preliminary report (abstract). Ann Oncol 11 (Suppl 4):A380.
29. Pfeilschifter J and Diel IJ (2000) Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 18:1570-1593.
30. Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, Hawle H, Thürlimann B, Mouridsen H, Campone M, Forbes JF, and Paridaens RJ, et al.; BIG 1-98 Collaborative and International Breast Cancer Study Groups (2009) Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 20:1489-1498.
31. Reeves PG, Nielsen FH, and Fahey GC, Jr (1993) AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 123:1939-1951.
32. Shi HF, Cheung WH, Qin L, Leung AH, and Leung KS (2010) Low-magnitude highfrequency vibration treatment augments fracture healing in ovariectomy-induced osteoporotic bone. Bone 46:1299-1305.
33. Siu WS, Qin L, Cheung WH, and Leung KS (2004) A study of trabecular bones in ovariectomized goats with micro-computed tomography and peripheral quantitative computed tomography. Bone 35:21-26.
34. van Meeuwen JA, Nijmeijer S, Mutarapat T, Ruchirawat S, de Jong PC, Piersma AH, and van den Berg M (2008) Aromatase inhibition by synthetic lactones and flavonoids in human placental microsomes and breast fibroblasts-A comparative study. Toxicol Appl Pharmacol 228:269-276.
35. Wang G, Li W, Lu X, Bao P, and Zhao X (2012) Luteolin ameliorates cardiac failure in type I diabetic cardiomyopathy. J Diabetes Complications 26:259-265.
36. Wang Y, Man Gho W, Chan FL, Chen S, and Leung LK (2008) The red clover (Trifolium pratense) isoflavone biochanin A inhibits aromatase activity and expression. Br J Nutr 99:303-310.
37. Yue W, Zhou D, Chen S, and Brodie A (1994) A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res 54:5092-5095.
38. Zhou DJ, Pompon D, and Chen SA (1990) Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res 50:6949-6954.